Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

The Melanoma Epidemic: Real or Imaginary? Critical Thinking and Clinical Judgment in the Interpretation of Disease, Data and Dogma

Description

The presentation discusses the marked rise in malignant melanoma cases over the past three decades across developed countries, portraying melanoma as the fastest-growing cancer in the U.S., with incidence rates doubling since 1980. Despite this rise, mortality rates have remarkably remained unchanged, leading to the question of whether this is a genuine epidemic or simply a product of overdiagnosis. The speaker emphasizes the necessity for caution in diagnosing melanoma while acknowledging the serious consequences of overdiagnosis for patients, including unnecessary surgeries and anxiety regarding their health, as well as damaging the credibility of dermatology as a specialty. Historical increases in awareness and screening efforts are identified as major contributors to the rising incidence, yet they have not correlated with a decrease in mortality. Notably, studies suggest that the increased diagnosis of melanoma cases might not reflect a true increase in malignant disease severity but rather an artifact of diagnostic practices akin to those seen in prostate and thyroid cancers. The presentation culminates in the assertion that despite heightened screening and public awareness efforts, no evidence exists that these interventions have meaningfully reduced melanoma mortality, suggesting that the actual lesions classified as melanoma may not be biologically malignant, and reinforcing the idea that there is no real melanoma epidemic.

View more

Conclusions

There has been a 128% increase in malignant melanoma incidence in developed countries since 1980, suggesting an epidemic.
Despite the increase in incidence, melanoma mortality rates have remained constant, questioning the validity of the melanoma epidemic.
This discrepancy suggests that melanoma may be overdiagnosed, possibly due to aggressive screening practices that do not correlate with biological malignancy.
The high rates of diagnosis without a corresponding rise in mortality raise concerns about the accuracy of melanoma diagnoses.
Patients may face significant consequences from overdiagnosis, including unnecessary surgeries and increased insurance costs, as well as psychological distress.
The perception of dermatology within the medical community could be negatively affected by potential overdiagnosis of melanoma.
Increased screening has not led to improved mortality outcomes, as similar trends have been observed in other types of cancer screenings, indicating a possible disconnect between diagnosis and actual mortality risk.
Epidemiological data suggest that the current increase in melanoma cases may not represent an actual increase in aggressive cancer but rather a result of increased diagnostic scrutiny and misclassification of non-malignant lesions.
Overall, the research suggests that the melanoma epidemic is largely an artifact of diagnostic changes rather than a genuine public health crisis.

SEER Cancer Statistics: Melanoma of the Skin. National Cancer Institute. Bethesda, MD seer.cancer.gov/statfacts/html/melan.html
Balch, C.M., Final Version of 2009 AJCC Melanoma Staging and Classification, JCO 27:36 6199-7206, 2009
Brenner H: Mortality from malignant melanoma in an era of nationwide skin cancer screening. Dtsch Arztebl Int 2015: 112: 627-8.
Swerlick and Chen: 1997, The Discordance in Incidence and Mortality of Melanoma, Mayo Clinic Proceedings. 1997.